BioSpace News Archive

Merck’s KEYTRUDA ® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma.

Olema Pharmaceuticals, Inc. announced the first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250, a complete estrogen receptor antagonist and a selective ER degrader in development for the treatment of metastatic breast cancer and other women’s cancers.

IsoPlexis today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller.

PrecisionOS ® has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market InVisionOS™ a patient specific planning tool using Virtual Reality (VR).

MEI Pharma, Inc. today announced that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma.

NeoGenomics, Inc. today announced that Mark Mallon, Chief Executive Officer, Bill Bonello, President - Informatics Division, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Stephens Annual Investment Conference 2021 held in Nashville, Tennessee on Friday, December 3, 2021 at 9:00am.

MYND Life Sciences Inc. is pleased and extremely grateful to acknowledge the financial contribution from the Government of Canada towards an important component of its research and development into the positive effects of psilocybin on treating diseases of the brain.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending Biologics License Application (BLA).

GT Biopharma, Inc. today announced that an abstract was accepted for presentation at the upcoming European Society for Medical Oncology (“ESMO”) Immuno-Oncology (“IO”) Congress 2021 to be held December 8-11, 2021 in Geneva Switzerland.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) along with partner PharmaMar (MSE: PHM) have announced the commercial availability of ZepzelcaTM (lurbinectedin) after receiving conditional approval by Health Canada in September 2021.